Moleculin Biotech Inc. Starts Enrollment For Study

Moleculin Biotech Inc. on Monday announced that it has started enrolling and dosing the first subject in its Phase 1b/2 study evaluating the efficacy of its treatment for soft-tissue sarcoma lung metastases, Monday. The clinical-stage pharmaceutical company will look at Annamycin as a standalone treatment in patients with sarcoma lung metastases in the U.S.

Moleculin Biotech Inc expects to have interim data from the study in the second half of 2022. Walter Klemp, Chairman and Chief Executive said that they are pleased to have commenced patient enrollment and dosing in this important program evaluating Annamycin, which we believe has the potential to address the limitations with current treatment options for STS lung metastases.

The company said that as the soft-tissue sarcomas grow in the lungs, it becomes more difficult to treat. Annamycin is a next-generation anthracycline, a type of chemotherapy drug that prevents cell division. The treatment has shown it could accumulate sufficiently and lacks cardiotoxicit. The company has received orphan drug designation and fast track status by the U.S. Food and Drug Administration.

Moleculin Biotech Inc., a clinical-stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that as part of the annual reconstitution of the Russell stock indexes, Moleculin has been selected to be added to the Russell 2000® Index effective after the close of the U.S. equity markets on June 25, 2021. The Russell 2000® Index measures the performance of the small-cap segment of the US equity market.The Russell 2000® Index is a subset of the Russell 3000® Index representing approximately 10% of the total market capitalization of that index. It includes approximately 2,000 of the smallest securities based on a combination of their market cap and current index membership.